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Stroke is the third cause of mortality and one of most frequent causes of long-term neurological disability, as well as a complex
disease that results from the interaction of environmental and genetic factors. The focus on genetics has produced a large number
of studies with the objective of revealing the genetic basis of cerebrovascular diseases. Furthermore, pharmacogenetic research has
investigated the relation between genetic variability and drug eﬀectiveness/toxicity. This review will examine the implications of
pharmacogenetics of stroke; data on antihypertensives, statins, antiplatelets, anticoagulants, and recombinant tissue plasminogen
activator will be illustrated. Several polymorphisms have been studied and some have been associated with positive drug-gene
interaction on stroke, but the superiority of the genotype-guided approach over the clinical approach has not been proved yet; for
this reason, it is not routinely recommended.
1.Introduction
Stroke is the third cause of mortality and one of most freq-
uent causes of long-term neurological disability. Well-esta-
blished risk factors for stroke include increasing age, hyper-
tension, diabetes mellitus, cigarette smoking, obesity, heart
disease, atrial ﬁbrillation and sedentary [1, 2]. However, a
signiﬁcant number of patients experience stroke in the ab-
sence of any risk factors; a hypothesis is that many risk fac-
tors have not been recognized yet, including genetic risk fac-
tors. The role of genetics has been evidenced through
studies on twins and family history. Twin studies have
shown that monozygotic twins are 1.6 more likely to
beconcordantforstrokethandizygotictwins[3].Familyhis-
tory of stroke is a well-deﬁned risk factor (OR 1.76 95% CI
1.7–1.9) [3].
Given these data, genetic studies have increasingly been
performed with the objective of revealing the genetic basis of
cerebrovasculardiseases.Geneticstudieshavebeenproposed
to (1) reveal the pathogenetic basis of stroke, which might
become a therapeutic target for new drugs, (2) optimize risk
assessment, (3) identify populations requiring more aggres-
sive therapeutic strategies, and (4) choose the optimal drug
therapy by assessing the risk/beneﬁt ratio based on genetic
characteristics[4].Thelatterapplicationhasbeenextensively
studied in pharmacogenetic studies [5–7]. Recently, genetic
studies have moved to “pharmacogenomic” that involve a
genome-wide association approach which scans the entire
genome looking through thousands of genetic variants; these
hypothesis-free studies have the aim of discovering novel
genes associated with a speciﬁc disease. This review has the
aim of reporting on the latest developments regarding phar-
macogenetics and pharmacogenomics of stroke, focusing on
the most commonly used drugs in the acute phase, for pri-
mary and secondary prevention.
2. Methods
Thisreviewwasplannedusingkeywordssuchas“pharmaco-
genetics” or “pharmacogenomics” and “stroke” to search lit-
erature. These words were combined with “antihypertensive
agents,” “statins,” “hydroxymethylglutaryl-CoA Reductase
Inhibitors,” “tissue plasminogen activator,” “anticoagulants,”
“vitamin K antagonist,” “antiplatelets,” “cyclooxygenase
Inhibitors,” “aspirin,” “clopidogrel,” and “acetil salicylic acid/
dipyridamole.”
The following electronic databases were searched: MED-
LINE (1995-June 11 2011) and EMBASE (1995-June 11
2011). One of the researchers (SA) read all the abstracts and2 Stroke Research and Treatment
selected all articles that included either “stroke” as outcome
in primary prevention studies or as the target population in
acute stroke treatment or secondary prevention studies. If
any doubt was raised on an article’s relevance, a second opin-
ion was formulated by VC.
3. Results
Inthissection,pharmacogeneticstudiesinvolvingdrugscur-
rently used for ischemic stroke (prevention or acute phase
therapy) are reviewed.
3.1. Antihypertensive Agents. Hypertension is the most com-
mon stroke risk factor [41]. β1a n dβ2 adrenergic receptor
(AR) plays a major role in cardiac disease; their codifying
genes have been associated with response to antihypertensive
drugs. β1-AR gene interacted with beta-blocker (BB) ther-
apy. Stroke risk has been shown to be higher in rs#2429511
carriers treated with BB (OR: 1.24, 95% CI: 1.03–1.50).
On the contrary, BB therapy did not interact with β2-AR
gene variants on the risks of ischemic stroke (Table 1)[ 14].
A large randomised trial on treated hypertensive patients,
enrolled to add either verapamil SR or trandolapril
(International Verapamil SR-Trandolapril Study, INVEST
study), focused on the genetic component of hypertension
(INVEST-GENES) (Table 1)[ 8, 9, 17, 18, 20]. One of the
papers derived from this study examined the polymorphism
of α-adducin (ADD1) Gly460Trp and race. The authorschose
this polymorphism because α-adducin, a cytoskeleton pro-
teinrelatedwithsodiumsensitivityanddiureticseﬃcacy,has
been linked to essential hypertension [42]. The results did
not evidence any diuretic-genotype interaction [20]. On the
contrary, a population-based case control study on the same
polymorphism found that diuretics protected ADD1 460 Trp
carriers from combined nonfatal MI/nonfatal stroke out-
come. Other antihypertensive agents (e.g., beta blockers,
ACE inhibitors, and calcium-channel blocker) did not show
the same eﬀect [19].
The randomised INVEST-GENES study also investigated
the relation between subunit β1 of the gene that encodes
for a conductance calcium and voltage-dependent potassium
channel (KCNMB1) genotype and response to calcium anta-
gonists. The results showed that carriers of the Leu 110 poly-
morphism have a reduced risk of combined death, MI, and
stroke when assuming verapamil SR to treat hypertension
[9]. In addition, the same research group focused on G-pro-
tein-coupled receptor kinases (GRKs), receptors involved in
beta-adrenergic signalling. GRK2 SNPs (rs1894111 G > A)
and GRK5 Gln41Leu polymorphism were investigated in pa-
tients treated with atenolol or hydrochlorothiazide. The au-
thorsconcludedthatGRK41Leuvariantdidnotinteractwith
any of the studied treatment regarding a combined cardio-
vascular outcome including death, MI, and stroke [8]. Final-
ly, Pacawnosky investigated for an association between nitric
oxide synthase (NOS 3)p o l ym o rp h i s m[ 18], beta-adrenergic
receptor gene (ADRB1 and ADRB2)[ 17], and response to
diﬀerent antihypertensive agents. The ﬁrst study focused on
two NOS 3 polymorphisms since nitric oxide regulates vas-
cular tone and is associated with many cardiac diseases [43];
no outcome or drug interaction was associated with geno-
type [18]. Also the second study did not evidence any geno-
type-drug interaction on stroke [17].
A population-based prospective cohort study focused on
the renin-angiotensin system which is aﬀected by ACE-inhi-
bitors and BB (Table 1)[ 15, 16]. Neither of the studies ob-
served any interaction between drug use and genotype when
stroke was considered as outcome [15, 16].
The genetics of hypertension-associated treatment (Gen-
HAT) study investigated the ACE insertion/deletion (ACE
I/D) polymorphism in a large population of hypertensive pa-
tients with one or more cardiovascular risk factors. This ran-
domised study did not report any association between treat-
ment, genotype, and primary or secondary outcomes [11].
The same result was replicated in a more articulated in-
vestigation on the ACE gene and 12 other polymorphisms
(ADD1 Gly460Trp, β1AR Gly389Arg, β2AR Arg16Gly, β2AR
Gln27Glu, β3AR Trp64Arg, AGT Met235Thr, Aldosterone syn-
thase promoter C-344T, Type 1 angiotensinogen receptor
A1166C, bradykinin 2 receptor I/D, CYP2C9 ∗ 2 versus
CYP2C9 ∗ 1, CYP2C9 ∗ 3 versus CYP2C9 ∗ 1,Gp r o t e i n
β3-subunit C825T)[ 10]. This study was the product of the
randomised LIFE (Losartan Intervention for Endpoint re-
duction in Hypertension) study trial, which included pa-
tients with hypertension and left ventricular hypertrophy
treated with losartan versus atenolol. The authors did not
evidence any genetic-drug interaction on diﬀerent outcomes
such as blood pressure and heart rate control, composite ad-
verse cardiovascular outcome, cardiovascular death, MI, and
stroke; in fact, they concluded that the clinical superiority of
losartan in 25% stroke reduction compared to atenolol was
not explained by these susceptibility genes [10].
A role in modulating antihypertensive agents has been
suggested for the gene which codes for the precursor of atrial
natriuretic polypeptide (NPPA gene). The polymorphism of
this gene was studied by the GenHAT study [12]. The ob-
jective was to demonstrate that minor NPPA alleles in the
T2238C or G664A variants had lower rates of primary out-
come events compared with common allele homozygotes, if
treated with diuretics. Subjects randomly receiving amlodip-
ine, chlorthalidone, lisinopril, or doxazosin were included in
a genetic for treatment interaction analysis. Carriers of the
minor C allele had more favourable stroke outcome when
taking diuretics, whereas TT allele carriers had better stroke
outcome when receiving a calcium channel blocker [12].
GenHAT [13] also showed that stroke risk was higher on
lisinopril versus amlodipine in common GG homozygotes of
ﬁbrinogen beta (FGB) gene, which codes for a polypeptide of
the coagulation factor ﬁbrinogen. On the contrary, variant
A allele carriers on lisinopril had slightly lower stroke risk.
Finally, a pharmacogenetic study on perindopril failed to de-
monstrate a role for ACE I/D polymorphism on stroke [21].
3.2. Statins. The most currently used drugs for hypercholes-
terolemia are statins; although very eﬀective, they induce a
signiﬁcant rate of adverse events such as myopathies andStroke Research and Treatment 3
Table 1: Antihypertensive agents.
Name Outcome Gene and variant Sample size/drugs used Eﬀect estimates and signiﬁcance
levels
INVEST-
GENES
[8]
Death/MI or stroke GRK2 SNPs (rs1894111 G > A)
GRK5 Gln41Leu
48/Verapamil SR,
atenolol
GRK5 41Leu decreased the risk of
adverse cardiovascular outcome
adjusted independently of treatment
(OR 0.535, 95% CI: 0.313–0.951)
INVEST-
GENES
[9]
Death/MI or stroke KCNMB1 Glu65Lys
KCNMB1 Val110Leu
5979 with
HTN/Verapamil SR,
atenolol
KCNMB1 110Leu had reduced risk of
composite outcome (HR 0.68 (95%
CI 0.47–0.998); this eﬀect was higher
in Verapamil SR (HR 0.587, 95% CI
0.33–1.04) than atenolol-treated
patients (HR 0.946, 95% CI
0.56–1.59)
LIFE
substudy
[10]
Cardiovascular events
13 polymorphisms
(angiotensin-converting enzyme
I/D, α-adducin Gly460Trp,
β1-adrenergic receptor
Gly389Arg, β2-adrenergic
receptor Arg16Gly,
β2-adrenergic receptor
Gln27Glu, β3-adrenergic
receptor Trp64Arg,
angiotensinogen Met235Thr,
aldosterone synthase promoter
C-344T, type 1 angiotensinogen
receptor A1166C, bradykinin 2
receptor I/D, CYP2C9 ∗2v e r s u s
CYP2C9 ∗1, CYP2C9 ∗3v e r s u s
CYP2C9 ∗1, G protein
β3-subunit C825T)
3503/Losartan, atenolol No signiﬁcant genotype-drug
interaction on the outcome
GEN-HAT
[11]
Primary: fatal
CHD/nonfatal MI.
Secondary: stroke,
all-cause mortality,
combined CHD, and
combined
cardiovascular disease
ACE I/D
37,939/chlorthalidone,
amlodipine, lisinopril,
or doxazosin
No signiﬁcant association with the
outcome was reported; no signiﬁcant
gene-drug interaction was found
GEN-HAT
[12]
Primary: fatal
CHD/nonfatal MI.
Secondary: stroke,
all-cause mortality,
combined CHD, and
6-mos systolic and
diastolic BP changes
NPPA SNP T2238C (rs5065)
NPPA SNP G664A (rs5063)
38,462 with
HTN/chlorthalidone,
amlodipine, lisinopril,
or doxazosin
NPPA T2238C TT variant
x “chlorthalidone versus amlodipine”
interaction was signiﬁcantly
associated stroke (HR 1.09 95% CI
0.95–1.26).
NPPA T2238C TT variant x
“chlorthalidone versus amlodipine +
lisinopril” interaction was
signiﬁcantly associated with stroke
(HR 1.09 95% CI 0.95–1.26).
NPPA T2238C CC variant x
“chlorthalidone versus amlodipine”
interaction was signiﬁcantly
associated with stroke (HR 1.18 95%
CI 0.72–1.90). Either NPPA T2238C
variant or NPPA G664A was not
signiﬁcantly associated with stroke
and “chlorthalidone versus
lisinopril,” “chlorthalidone versus
doxazosin”4 Stroke Research and Treatment
Table 1: Continued.
Name Outcome Gene and variant Sample size/drugs used Eﬀect estimates and signiﬁcance
levels
GEN-HAT
[13]
Primary: fatal
CHD/nonfatal MI.
Secondary: stroke,
heart failure, all-cause
mortality, end-stage
renal disease
FGB G455A
30 076 with
HTN/chlorthalidone,
amlodipine, lisinopril
Common GG homozygotes had
higher stroke risk on lisinopril versus
amlodipine (HR 1.38, P<0.001);
variant A allele carriers had slightly
lower risk on lisinopril versus
amlodipine (HR 0.96, P value for
interaction = 0.03)
Lemaitre
et al. [14] MI, ischemic stroke
ADRB1 (Seven SNPs plus
haplotype), ADRB2 (ﬁve SNPs
plus haplotypes)
938 cases with MI or
stroke/beta blocker
beta1-AR gene variation and
beta-blocker use showed a positive
interaction on ischemic stroke risk
(P = 0.04). Homozygosis or
heterozygosis for rs#2429511 variant
was associated with higher MI/stroke
combined risk in beta-blocker users
(OR 1.24 95% CI 1.03–1.50).
No interaction of ADRB2 with
beta-blocker use and outcomes
Rotterdam
study [15] MI, stroke AGT (M235T) 4097 with HTN/ACEI,
BB
No signiﬁcant gene-drug interaction
was found on stroke
Rotterdam
study [16] MI, stroke AGTR1 (C573T)
ACE (I/D)
4097 with HTN/ACEI,
BB
No signiﬁcant AGTR1 and ACE I/D
interaction on stroke risk with ACEI
or BB
INVEST-
GENES
[17]
Death/nonfatal
MI/nonfatal stroke
ADRB1 (Ser49GLy, Arg389Gly)
and ADRB2 (Gly16Arg,
Gln27Glu, 523 C > A)
5,895 CAD
patients/Verapamil SR,
atenolol
No association between any
haplotype and treatment on stroke
INVEST-
GENES
[18]
Death/nonfatal
MI/nonfatal stroke
NOS3-786T > C (rs2070744),
NOS3 Glu298 > Asp (rs1799983)
258 death/MI/stroke
versus 774 control
No genetic interaction with drugs
and composite outcome
Psaty et al.
[19] MI/nonfatal stroke ADD1 (Gly460Trp) Cases versus controls
ADD1 Trp460 variant had lower
stroke risk on diuretics (OR, 0.49;
95% CI, 0.32–0.77). The point
estimate of diuretic-adducin
interaction was SI 0.45 (95% CI
0.26–0.79) for the combined
outcome MI and stroke; separate
analyses yielded similar results: MI
(SI 0.41 95% CI 0.21–0.80) and
stroke (SI 0.53 95% CI 0.24–1.19)
INVEST-
GENES
[20]
Death/nonfatal
MI/nonfatal stroke ADD1 Gly460Trp
5,979 CAD
patients/Verapamil SR,
atenolol
ADD1 Trp460 black carriers had
higher combined outcome risk (aHR
2.62, 95% CI 1.23–5.58), compared
to whites (aHR 1.24 95% CI
0.90–1.71) and Hispanics (aHR 1.43
95% CI 0.86–2.39). No signiﬁcant
interaction between the ADD1
polymorphism and diuretic use for
either primary outcome or secondary
outcomesStroke Research and Treatment 5
Table 1: Continued.
Name Outcome Gene and variant Sample size/drugs used Eﬀect estimates and signiﬁcance
levels
PROGRESS
[21]
Fatal and nonfatal
stroke (ischemic or
hemorrhagic),
nonfatal MI/coronary
death, composite
nonfatal
stroke/nonfatal
MI/vascular death,
all-cause mortality,
dementia, and
cognitive decline
ACE I/D 5688 with stroke or
TIA/perindopril
No associations between ACE
genotypes and cerebrovascular
disease history or cardiovascular risk
factors was demonstrated. The ACE
genotype was not associated with the
long-term risks of stroke. The ACE
genotype did not modify the relative
beneﬁts of perindopril over placebo
abnormal transaminase levels. Recent pharmacogenetics
data has contributed to better understanding statin phar-
macokinetics and pharmacodynamic variability [44]. Phar-
macogenetic and dynamic properties have been extensively
studied, but only few studies included stroke as outcome
(Table 2)[ 22–25].
Apopulation-basedcohortstudyfocusedonapolipopro-
tein E, a protein involved in lipid clearance rate and conver-
sion together with the production of triglycerides and very
low-density lipoprotein. The Apo E gene encodes for three
alleles: E2, E3, and E4 [45]. The results did not show gene-
statin interaction with stroke; stroke risk was reduced in-
dependentlyofApoEgenotypeinstatinusers[24].Thesame
author examined the eﬀect of ACE I/D polymorphism on
stroke using the Gen-HAT data. None of the outcomes evi-
dencedsigniﬁcant ACEI/D-pravastatin interaction[25].The
randomised heart protection study focused on Kinesin
family member 6 (KIF) gene, whose variant has been asso-
ciated with reduced coronary events [46]. The authors did
notﬁndanysigniﬁcantinteractionbetweenthestudiedpoly-
morphism KIF Trp719Arg and simvastatin use for any of the
outcomes, including stroke [23]. The only study that yielded
positive results was a case-control study that involved patient
with MI and stroke. The authors focused on six genes that
havebeen associated to statin treatmentresponse: ATP-bind-
ing cassette subfamily B (ABCB1) gene that encodes for a
drug transporter involved in statins metabolism; CETP,h u -
man hepatic lipase gene (LIPC) and low density lipoprotein
receptor (LDLR), genes related to lipid metabolism;
HMGCR, the target protein of statins; NOS3,ak e yg e n ei m -
plicatedinmaintainingtheendothelium,whichinturnmed-
iates several eﬀects of statins [22]. The authors found 5 poly-
morphisms (one in CETP and 1 in LIPC) thathad signiﬁcant
interactions with statins on stroke outcome [22], the highest
signiﬁcance level was found in the CETP SNPs (rs5883),
whichwasassociatedwithstrokeriskinsimvastatinusers.No
gene level interactions were found for stroke [22].
3.3. Tissue Plasminogen Activator. Recombinant tissue plas-
minogen activator (rTPA) is the only licensed drug to treat
ischemic stroke in the acute phase (within 3–4.5 hours from
onset).Thisdrugisadministeredtotreatischemicstrokeand
restore blood ﬂow to the brain [47, 48]. The clinical beneﬁt
of rTPA is counterbalanced by a higher risk of hemorrhagic
complications; 2–10% of patients develops symptomatic
hemorrhagic transformations and 40% asymptomatic hem-
orrhagic events [49–51] .T h ef u n c t i o n a lr o l eo fr t - P Ai st o
convert plasminogen into plasmin, which has ﬁbrinolytic
activity. The higher activity of the enzyme produces hyper-
ﬁbrinolysis and consequently bleeding, whereas lower activ-
itycauseshypoﬁbrinolysisand,asaconsequence,thrombosis
or embolism [52]. Genetic association studies have sought
to investigate genetic proﬁles correlated with clinical and
pathophysiological rt-PA response (Table 3). Broderick et al.
[26, 53] examined the role of the ApoE phenotypes and
reported that rt-PA eﬃcacy was greater in acute stroke pa-
tients with an ApoE E2 phenotype (OR: 6.4; 95%, CI: 2.7–
15.3), whereas the outcome of placebo-treated patients with
orwithoutApo E E2 didnotdiﬀer[26].Conversely,aSpanish
group did not report on any association with Apo E geno-
type and hemorrhagic risk and recanalisation rate after thro-
mbolytictreatment[27].Thesamegroupexploredthehypo-
thesis that matrix metalloproteinase-9 gene (MMP-9), which
codes for proteins associated with blood-brain barrier dis-
ruption, was associated with hemorrhagic transformation in
rTPA-treated patients. However, the authors did not ﬁnd any
association between a MMP-9 C-1562T common polymor-
phism and hemorrhagic risk [32]. On the other hand, the
authors reported that thrombolytic intervention yielded
middle cerebral artery (MCA) recanalisation associated with
DD homozygosis of ACE I/D polymorphism; this has been
linked to procoagulant factors including PAI-1, ﬁbrinogen’s
levels as well as Factors VII and X activities [29]. Another
study of the same group has identiﬁed V34L factor XII poly-
morphism as a predictor of outcome with rTPA treatment;
good outcome was associated with VV genotype and low
ﬁbrinogen levels, while a higher risk of ineﬃcacy of throm-
bolytic therapy and mortality was found with L34 genotype
and high ﬁbrinogen levels [31]. In addition, Fernandez-
Cadenas and colleagues studied the inﬂuence of two genes
coding for ﬁbrinolysis inhibitors, thrombin-activatable ﬁbri-
nolysis inhibitor (TAFI), and plasminogen activator inhibi–
tor-1 (PAI-1) genes. They demonstrated that TAFI Thr325Ile
polymorphism predicted the absence of recanalisation with6 Stroke Research and Treatment
Table 2: Statins.
Author’s
name/study
name
Outcome Gene (variant) Sample size/drug Eﬀect estimates and ﬁndings
Hindorﬀ et al.
[22]
Nonfatal MI/nonfatal
stroke
ABCB1, CETP, HMGCR,
LDLR, LIPC, NOS3
865 with MI, 368 with
stroke and 2686
controls/statins
No gene-statin interactions
for stroke.
5 SNP-statin interactions on
stroke (one CETP, four LIPC);
no gene level association for
stroke; SNP level association:
two SNPs (one CETP, one
LDLR) for stroke.
The highest signiﬁcance was
found for stroke in CETP
rs5883 carriers on simvastatin
(OR 3.60 95% CI 1.22–7.70)
Heart
protection
study [23]
Major coronary event
(coronary death or nonfatal
MI), major vascular event
(major coronary event plus
revascularization or stroke)
KIF6 Trp719Arg
polymorphism (rs20455)
on vascular risk and
response to statin therapy
in from of the heart
protection study
18,348
participants/simvastatin
No signiﬁcant gene-statin
interaction with any of the
outcome, including stroke
Rotterdam
study [24] D e a t h ,M I ,s t r o k e A p oE( E 2 ,E 3 ,E 4 ) 7983 older than 55
yo/statins
No signiﬁcant gene-statin
interaction with any of the
outcome.
Statins reduce stroke risk
(aOR 0.50 95% CI 0.28–0.91)
independently of Apo E
genotype
GenHAT [25]
Primary outcome: all-cause
mortality, secondary
outcomes (fatal CHD and
nonfatal MI, CVD
mortality, CHD, stroke,
other CVD, non-CVD
mortality, stroke, and heart
failure)
ACE (I/D) 9467/pravastatin
No signiﬁcant gene-statin
interaction with any of the
outcome
t-PA infusion. On the contrary, PAI-1 4 G/5 G polymor-
phism did not inﬂuence recanalisation rate. However, the
combination of these two polymorphisms doubled the risk
of negative response to therapy [30]. A recent study using
a candidate gene approach has explored the association of
263 SNPs and recanalisation rate in TPA-treated patients;
cluster of diﬀerentiation 40 (CD40) 1C > T and matrix Gla
protein (MGP)-7A > G polymorphism were both associated
with reocclusion although only the latter was associated with
neurological worsening at 24h [28]. This may be due to the
role of CD40 in thrombosis and inﬂammation [54], while
MGP gene might have a protective role in atherosclerosis
[55]. To date, GWAs has not been performed on human sub-
jects.
3.4. Anticoagulants. Anticoagulation is ﬁrst-line treatment
for cardioembolic stroke. Although these drugs are eﬀective
in almost 60% of cases, the hemorrhagic risk is double and
even higher in the ﬁrst period of therapy [1]. Recent acqui-
sition on pharmacogenetics of warfarin has been suggested
to be able to predict the optimal initial dosage of warfarin
using a genotype-guided approach (Table 4). This approach
promises to adequately prevent stroke and to minimize
hemorrhagicrisk.Severalcandidategenestudieshavemainly
focused on cytochrome P450 (CYP) and vitamin K epoxide
reductasecomplexsubunit1(VKORC1)[56,57].Cytocrome
P 450 metabolises in the liver S-warfarin by CYP2C9 and
R-warfarin by the CYP1A1, CYP1A2, and CYP3A4; these en-
zymes aﬀect warfarin kinetics, and several SNPs of CYP450
have been correlated with its sensitivity [58]. The VKORC1
enzyme converts the epoxide into reduced vitamin K; how-
ever warfarin inhibits this reaction. As a consequence, the
physiologic role of vitamin K, which produces γ-carboxy-
lation of several coagulation factors (prothrombin, factor
VII, IX, and X), is inhibited.
Several groups have studied the role of VKORC1 in war-
farin/acenocoumarol dose ﬁnding, dose maintenance, and
bleeding risk associated with these drugs [33, 34, 59–61].
Only two studies have focused on patients receiving vitaminStroke Research and Treatment 7
Table 3: Tissue plasminogen activator.
Author’s name/study
name Outcome Gene (Variant) Sample Size/drug Eﬀect estimates and ﬁndings
Broderick et al.
2001 [26]
Favourable outcome (NIHSS of
0o r1 ,B a r t h e lI n d e xo f9 5o r
100, Modiﬁed Rankin Scale of 0
or 1, and a Glasgow Outcome
Scale of 1.)
ApoE (E2, E3, E4)
409 ischemic
stroke/rTPA versus
PB within 3 hours
ApoE E2 phenotype-rt-PA interaction
was associated with good outcome at 3
months (OR: 6.4; 95% CI: 2.7–15.3).
Apo E4 phenotype not related to
favorable 3 month outcome, response
to t-PA, 3-month mortality, or risk of
intracerebral hemorrhage
Fern´ andez-Cadenas
et al. [27]
Recanalization rate, NIHSS at
48 hours and mRS score at 3
months, heamorrhagic
transformation
ApoE (E2, E3, E4)
77 ischemic
stroke/rTPA
within 3 hours
No signiﬁcant association of ApoE
genotype and the studied outcome
Del R´ ıo Esp´ ınola
et al. [28] Reocclusion rate
236 SNPs form
candidate genes for
vascular risk factor
222 ischemic
stroke/rTPA
rs1883832 SNP from CD40 gene (OR:
0.077; 95% CI: 0.009–0.66) and
rs1800801 SNP from the MGP gene
(OR 15.25; 95% CI: 2.23–104.46) were
independently associated with
reocclusion after adjustment for
clinical predictors
Fern´ andez-Cadenas
et al. [29] Recanalization ACE (I/D)
96 ischemic
stroke/rTPA
within 3 hours
ACE DD homozygosis was
signiﬁcantly associated with
recanalization rate following rTPA
(OR: 4.3 95% CI: 1.35–13.49).
No relation was found between ACE
I/D polymorphism and symptomatic
hemorrhagic complications. No
association between ACE genotypes
and Factor VII or Factor X activities
Fern´ andez-Cadenas
et al. [30] Recanalization PAI-1 4G/5G
TAFI (Thr325Ile)
139 with ischemic
stroke/TPA within 3
hours
PAI-1 4 G/5 G was not associated with
recanalization.
TAFI Thr325Ile polymorphism was
associated with recanalization
resistance (OR 5.6 95% CI 1.2–20).
Combination of TAFI and PAI-1
polymorphisms double the risk of
absence of recanalization (OR: 11.1;
95% CI: 1.4–89.8)
Gonz´ alez-Conejero
et al. [31] Death, recanalization Factor XIII (FXIII)
V34L
200 with ischemic
stroke/TPA within 3
hours
FXIII 34 L carriers had higher death
risk than V/V (OR 2.50 95% CI
1.00–7.06); high ﬁbrinogen levels
higher risk than lower levels (OR 2.72
95% CI 1.01–7.44); FXIII 34L and
high ﬁbrinogen level higher risk than
FXII V and low ﬁbrinogen (OR 5.74
95% CI 1.51–11.56).
No diﬀerence in recanalization rate
Montaner et al. [32] Hemorrhagic transformation MMP9 (C1562T)
61 with ischemic
stroke/TPA within 3
hours
The polymorphism studied does not
increase hemorrhagic risk
Kantagonistfollowingcardioembolicstroke.Onefoundthat
the time and cumulative dosage of phenprocoumon needed
to achieve target 2-3 INR ratio were associated with the
presence of the VKORC1 C283 + C837T (rs2359612)p o l y -
morphism. Carriers of TT genotype needed shorter time to
achieve target INR ratio (3.2 days) compared to CC carriers
(6.5 days) [33]. The second paper evaluated the roles of
VKORC1, gamma-glutamyl carboxylase (GGCX), calumenin
(CALU), and cytochrome P450 2C9 (CYP2C9)i nw a r f a r i n
maintenance dose on Japanese stroke suﬀerers. Of the twelve8 Stroke Research and Treatment
Table 4: Anticoagulants and antiplatelets.
Author’s name/study
name Outcome Gene (Variant) Sample size/drug Eﬀect estimates and ﬁndings
Anticoagulants
Arnold et al. [33] Dose ﬁnding VKORC1 C283 + 837C →
T (rs2359612)
49 with cerebrovascular
disease/phenprocoumon
VKORC1 TT carriers reached an
INR of 2-3 after a mean time of
3.2 days (n = 5), CT carriers
after 4.4 days (n = 27), and CC
carriers after 6.5 days (n = 15)
Kimura et al. [34] Warfarin maintenance
dose
(VKORC1),
gamma-glutamyl
carboxylase (GGCX),
calumenin (CALU), and
cytochrome P450 2C9
(CYP2C9)
93 Japanese on stable
anticoagulation therapy
1639G > A (P = 0.004) and
3730G > A genotypes
(P = 0.006) in VKORC1, the
8016G > A genotype in GGCX
(P = 0.022), and the 42613A > C
genotype in CYP2C9 (P = 0.015)
were associated with eﬀective
warfarin dose
Antiplatelets
Meta-analysis of 9
diﬀerent studies
(CLARITY TIMI 28,
EXCLESIOR,
TRITION TIMI 38,
AFIJI, FASSTS-MI,
RECLOSE, ISAR,
CLEAR PLATELETS,
Intermountain) [35]
Composite outcome
(cardiovascular
death/MI/stroke) and
stent thrombosis
CYP2C19/1 or 2 reduced
function alleles (∗2, ∗3,
∗4, ∗5, ∗6, ∗7, and ∗8)
9685 patients (91% had
PCI, 54% had
ACS)/clopidogrel
Carriers of 1 (HR 1.55; 95% CI,
1.11–2.17) or 2 (HR 1.76; 95%
CI, 1.24–2.50) reduced-function
CYP2C19 alleles had higher risk
of composite outcome events
TRITON-TIMI 38
[36]
Composite outcome
(cardiovascular
death/MI/ischemic
stroke)
CYP2C19/1 or 2 reduced
function alleles (∗2, ∗3,
∗4, ∗5, ∗6, ∗7, and ∗8)
ABCB1/3435C → T
2932 patients with ACS
undergoing
PCI/clopidogrel versus
prasugrel
TT homozygotes of ABCB1
genotype had increased risk of
the composite outcome
compared to CT or CC carriers
(HR 1.72, 95% CI 1.22–2.44).
Carriers of a CYP2C19
reduced-function allele only
(Kaplan-Meier event rate
11.5%), ABCB1 3435 TT
homozygotes only
(Kaplan-Meier event rate
12.6%), or both (Kaplan-Meier
event rate 13.6%) had increased
risk of composite outcome
(pooled HR 1.97, 95% CI
1.38–2.82).
No signiﬁcant
genotype-prasugrel interaction
was reportedStroke Research and Treatment 9
Table 4: Continued.
Author’s name/study
name Outcome Gene (Variant) Sample size/drug Eﬀect estimates and ﬁndings
PLATO [37]
Composite outcome
(cardiovascular
death/MI/stroke)
CYP2C19/1 or 2 reduced
function alleles
ABCB1/3435C → T
10285 patients with
ACS undergoing
non-CABG/clopidogrel
versus ticagrelor
Either with (HR 0.77, 95% CI
0.60–0.99) and without (0.86,
0.74–1.01, P = 0.0608) any
CYP2C19 reduced-function
alleles patients on ticagrelor
experienced lower risk of
composite outcome compared to
patients on clopidogrel
(interaction P = 0.46).
Independently of ABCB1
genotype, patients on ticagrelor
had lower risk of the composite
outcome compared to
clopidogrel users (interaction
P = 0.39; HR 0.71, 95% CI
0.55–0.92).
No signiﬁcant interaction was
found on treatment and
genotype regarding major
bleeding
PAPI study and
Mount Sinai study
[38]
Composite outcome
(cardiovascular death,
MI, ischemic stroke,
stent thrombosis,
unplanned target vessel
revascularization,
unplanned nontarget
vessel revascularization,
hospitalization for
coronary ischemia)
GWA
429 white healthy Amish
individuals/clopidogrel;
results replicated in 227
undergoing PCI
13 SNPs in 10q24 region, where
CYP2C18–CYP2C19–CYP2C9–
CYP2C8 gene cluster is found,
were associated with reduced
response to
clopidogrel. CYP2C19 ∗2a l l e l e
carriers were at higher risk for
composite outcome (adjusted
HR 2.42 95% CI 1.18–4.99)
Clappers et al. [39]
Composite outcome
(cardiovascular
death/MI/stroke)
COX-1/C50T
496 admitted to
Coronary Care Unit for
diﬀerent reasons/aspirin
No interaction was found on
genotype and aspirin for the
composite outcome
Hillarp et al. [40]n . a .
COX-1/C116T, del
137–142, C144T, G6841A,
G7331C, A7742A,
C10427A, C10608A, del
10675A, G12254A,
T12378C, G19187A,
C19242T, G19255A
68 with recurrent
stroke/ASA
14 variants of the Cox-1 gene
were identiﬁed and 7 involved
amino acid substitutions of the
Cox-1 molecule. None of the
mutations were located near the
catalytic site
ABCB1: ATP-binding cassette subfamily B, ACEI: angiotensin convertin enzyme inhibitors, ACE I/D: angiotensin convertin enzyme insertion/deletion, ACS:
acute coronary syndrome, ADD1: α-adducin, ADRB: β-adrenergic receptor, AGT: angiotensinogen, AGTR1: angiotensin receptor II type 1, APO E: apolipo-
protein E, BP: blood pressure, CABG: coronary artery bypass graft, CAD: coronary heart disease, CD: cluster of diﬀerentiation, CEPT: cholesteryl ester trans-
fer protein, CHD: coronary artery disease, COX: cyclooxygenase, CVD: cerebrovascular disease, CYP: cytochrome P, FGB: ﬁbrinogen beta, GRK: G-protein-
coupledreceptorkinase,GWA:genome-wideassociation,HMG-CoR:hydroxyl-methylcoenzymeAreductase,HR:hazardratio,HTN:hypertension,KCNMB:
conductance calcium and voltage-dependent potassium channel, KIN 6: kinesin family member 6, LDLR: low-density lipoprotein receptor, LIPC: human
hepatic lipase, MGP: matrix Gla protein, MI: myocardial infarction, MMP: matrix metalloproteinase, NIHSS: National Institute of Health stroke scale, NOS:
nitric oxide synthase, NPPA: atrial natriuetic polypeptide precursor, OR: odds ratio, PAI: plasminogen activator inhibitor, PCI: percutaneous coronary inter-
vention, SI: sinergy index, TAFI: thrombin-activable ﬁbrinolysis inhibitor, verapamil SR: verapamil-sustained release, VKORC1: vitamin K epoxide reductase
complex subunit 1.10 Stroke Research and Treatment
SNPs analysed, the authors found that the 1639G > A, 3730G
>AVK ORC1genotypes;the8016G>AGGCX genotype,and
the 42613A > CC Y P 2 C 9genotype were associated with dose
maintenance. Thus, the variation in warfarin dose was ex-
plained for 33.3% by age, sex, weight, and three genetic poly-
morphisms (VKORC1-1639G > A, CYP2C9 42613A > C,
GGCX 8016G > A). The importance of these loci has been
recentlyconﬁrmedusinggenome-wideassociationstudiesin
acenocoumarol-treated patients [62, 63]. These studies
found that the SNPs with the highest signiﬁcance level were
located in chromosome (cr.) 16 (rs10871454 and rs9923231)
linkedtoVKORC1andcr.10(rs4086116andrs105791)link-
ed with CYP2C9 gene. After adjusting for these two SNPs,
two other polymorphisms reached signiﬁcant association
with acenocoumarol: rs2108622 within CYP4F2 gene on
cr.19 and rs1995891 within CYP2C18 on cr. 10 [62, 63].
3.5. Antiplatelets. Antiplatelet drugs are commonly used
treatment for ischemic noncardioembolic stroke [1].
3.5.1. Aspirin. Aspirin is the more commonly used drug of
this class, and its eﬃcacy ranges between 13% and 25%. Its
physiological role is to acetylate serine residue 530 in the
active site of cyclooxygenase-1 (COX-1), sterically inhibiting
the metabolism of arachidonic acid and consequently reduc-
ing thromboxane A2 (TxB2), which activates platelets.
Numerous studies have investigated the genetic basis associ-
ated with recurrence of ischemic event in aspirin-treated pa-
tients (e.g., aspirin failure) (Table 4).
COX-1C50Tallelehasbeencorrelatedwithahigherlevel
of 11-dehydro-TxB2, both before and after aspirin; however,
the haplotype studied did not conﬁrm a genetic basis for
aspirinfailure[64,65].Inaddition,thispolymorphismisnot
associated with a higher risk of stroke [39].
An interesting study compared the COX-gene sequence
of patients with recurrent stroke (at least with two episodes)
on aspirin and healthy subjects. The study found fourteen
SNPs, and half of these lead to amino-acid substitutions;
how-ever, none of these variations was located near the COX
catalytic site, thus this genetic polymorphisms could not
explain the failure to respond to aspirin in this population
of stroke patients [40].
3.5.2. Clopidogrel. Clopidogrel is an oral, thienopyridine
antiplatelet drug that irreversibly inhibits the P2Y12 subtype
of ADP receptor, which has a major role in platelet aggrega-
tion. Clopidogrel has proven to be less eﬀective in carriers
of CYP2C19-reduced function allele [37, 38, 66]. These data
have been conﬁrmed in a recent meta-analysis that pool-
ed 9 randomised trails for acute coronary syndrome or per-
cutaneous coronary intervention; either homozygosis or het-
erozygosis carriers experience higher risk of stroke (Table 4)
[35].Thiscouldbecausedbyarelativereductionintheactive
metabolite of the drug, or by an insuﬃcient inhibition of
platelet aggregation. At a clinical level, CYP2C19 allele
carriers have major adverse cardiovascular events, including
stroke [35]. The TRITON TIMI 38 study on patients with
acute coronary syndrome treated with PCI following clopi-
dogrel versus another thienopyridine, “prasugrel,” explored
the role of ABCB1, a glycoprotein that might aﬀect clopidog
reltransportandmetabolism.ThepolymorphismonABCB1
3435C → Twascorrelatedtoasigniﬁcantincreaseinadverse
outcome including cardiovascular death, MI, or stroke (P =
0.0064). Speciﬁcally, TT homozygote patients had a 72% in-
creased risk of the primary endpoint compared with CT/CC
individuals [36]. This result might be a consequence of the
absolutereductioninmaximumplateletaggregationthathas
beenevidencedinhealthysubjectsenrolledinthesamestudy
[36].Furthermore,thePLATOstudyexploredthesamepoly-
morphisms in noncoronary artery bypass graft patients on
clopidogrel versus ticagrelor, a novel ADP receptor blocker
that does not need hepatic activation, and so is not inﬂuen-
ced by CYP2C19 alleles. Patients on ticagrelor were less likely
to experience stroke independently of CYP2C19 or ABCB1
genotype. In addition, no speciﬁc genotype-drug interaction
was associated with any major bleeding risk [37]. Finally, an
important GWA study has been performed on a healthy
Amish population and found a positive association with
clopidogrel response measured by ADP platelet aggregation
percentage and 10q24 region (Table 4). This region contains
CYP2C19 ∗ 2 genotype, which accounts for approximately
12% of the variation in clopidogrel response [38]. In ad-
dition, this study found a relevant association between this
CYP2C19 ∗ 2 variant and event-free survival of adverse car-
diovascular outcome in an independent population of 227
patients that underwent percutaneous coronary intervention
[38].
4. Conclusions
Pharmacogeneticsofstrokeisapromisingapproachforopti-
mizing treatment strategies aimed at decreasing stroke inci-
dence and recurrence. Many candidate gene studies have
examined the roles of polymorphisms on stroke treatment,
and some of these have been replicated in GWA studies.
H o w e v e r ,f e ws t u d i e sh a v ec o n s i d e r e ds t r o k ea sa ni n d e p e n -
dent outcome, probably due to the relatively small number
of events in the trails.
Antihypertensive agents are the most extensively studied
drug class. Some polymorphisms have been consistently
identiﬁed but results remain controversial, probably due to
diﬀerences in study designs and methods, small sample sizes,
and short durations of follow-up [67].
Statins and stroke have failed to ﬁnd any interaction with
most of the studied polymorphism. In addition, GWAs that
consider stroke as an outcome are not available.
Tissue plasminogen activator has been investigated only
in small studies on acute intravenous thrombolysis; thus,
the pharmacogenetic data need to be reproduced in larger
trails, and GWAs should be planned on humans in order to
move forward in this ﬁeld. Interestingly, a GWA study on
ischemic rats has shown the genes regulated by rTPA treat-
ment where diﬀerent from the ones involved in ischemic
stroke. In addition, gene expression proﬁles diﬀered when
reperfusion was or was not achieved [68]. If these resultsStroke Research and Treatment 11
weretobereplicatedonhumans,bloodplasmacouldbeused
tomonitorgeneexpressionproﬁles,whicharediverselyasso-
ciated with stroke and rtPA vessel recanalisation.
Anticoagulants dose variability has been consistently re-
portedtobeexplainedbyCYP2C9andVKORC1forthe33%
and up to the 58% when adding clinical information [69].
For this reason, the United States Food and Drug Admini-
stration suggests testing for these two polymorphisms in
order to achieve stable dose and to avoid major hemorrhagic
events. Although the pharmacogenetic approach on warfarin
is feasible in clinical practice [70]; its use in improving out-
come (i.e., shorter time to achieve range INR, more stable
dosing, greater percentage of time in therapeutic range,
and lesser major bleeding events) over the classical clinical
approach has been proven in only small samples [71, 72];
for this reason, larger studies (GIFT, COAG, and EU-PACT)
are ongoing to demonstrate the usefulness of the genetic ap-
proach and clinical algorithms (see www.clinicaltrials.gov/)
on outcome improvement. Unfortunately, genotype-guided
warfarin dosing has not been demonstrated to be cost eﬀec-
tive [73]. Finally, in the near future, vitamin K antagonists
could be gradually replaced in many indications with the
neweranticoagulants(e.g.,Dabigatran,Apixaban,andRivar-
oxaban), which do not require monitoring and dose adjust-
ment [74–76].
Antiaggregants: genetic studies on aspirin failure in re-
current stroke patients have been unsuccessful in ﬁnding
their genetic determinant. Several polymorphisms have been
linkedtopoorclinicalresponsetoclopidogrel,buttodate,no
study has proven the usefulness of the pharmacogenetic ap-
proach with clopidogrel in improving outcome. For this rea-
son, the ACCF/AHA [77] disagreed with the FDA regarding
their decision to add a warning on clopidogrel label recom-
mendinggenetictestingwhenprescribingitfortheﬁrsttime.
However, several studies, focusing on coronary disease, not
on stroke, are ongoing: GeCCO, RAPID GENE, TARGET
PCI, and GIANT (see http://www.clinicaltrials.gov/).
The future availability and low cost of technology will
allow for the screening of a large number of genetic deter-
minants. This will lead to the description of polymorphisms
that aﬀect drug pharmacokinetics and dynamics in each
given patient. Furthermore, this information will optimize
the eﬃcacy/toxicity ratio. Although promising, the results of
pharmacogeneticstudiesneedtobeconﬁrmedinprospective
randomised trials of comparative eﬀectiveness, comparing
the classical clinical and the genotype-guided approach, be-
forebeingusedinclinicalsettings.Furthermore,nostudyhas
explored yet the clinical usefulness of the genetic approach in
reducing adverse events. For these reasons, although promis-
ing, the genotype-guided approach for drug prescriptions is
not routinely recommended [56].
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